| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 90 | 2024 | 1513 | 15.000 |
Why?
|
| Androgen Antagonists | 23 | 2019 | 114 | 5.900 |
Why?
|
| Prostate-Specific Antigen | 25 | 2022 | 247 | 4.260 |
Why?
|
| Rectum | 10 | 2020 | 97 | 2.980 |
Why?
|
| Radiotherapy, Intensity-Modulated | 15 | 2018 | 67 | 2.780 |
Why?
|
| Salvage Therapy | 17 | 2018 | 193 | 2.760 |
Why?
|
| Prostatectomy | 21 | 2024 | 333 | 2.640 |
Why?
|
| Radiotherapy Dosage | 29 | 2023 | 185 | 2.480 |
Why?
|
| Radiotherapy, Conformal | 12 | 2018 | 55 | 2.470 |
Why?
|
| Radiation Injuries | 11 | 2023 | 142 | 2.280 |
Why?
|
| Quality of Life | 25 | 2024 | 1921 | 2.250 |
Why?
|
| Prostate | 12 | 2022 | 421 | 2.140 |
Why?
|
| Organs at Risk | 7 | 2023 | 23 | 2.020 |
Why?
|
| Brachytherapy | 11 | 2024 | 74 | 1.850 |
Why?
|
| Neoplasm Grading | 23 | 2022 | 267 | 1.810 |
Why?
|
| Contraceptives, Oral | 4 | 2017 | 38 | 1.720 |
Why?
|
| Emotions | 4 | 2016 | 364 | 1.660 |
Why?
|
| Proton Therapy | 5 | 2021 | 120 | 1.630 |
Why?
|
| Receptors, Mineralocorticoid | 3 | 2016 | 15 | 1.580 |
Why?
|
| Aged | 67 | 2024 | 18982 | 1.410 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2019 | 1114 | 1.400 |
Why?
|
| Male | 108 | 2024 | 59714 | 1.380 |
Why?
|
| Glioma | 13 | 2016 | 491 | 1.320 |
Why?
|
| Radiotherapy | 12 | 2020 | 139 | 1.280 |
Why?
|
| Facial Expression | 4 | 2016 | 28 | 1.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2018 | 253 | 1.210 |
Why?
|
| Adenocarcinoma | 7 | 2017 | 989 | 1.190 |
Why?
|
| Methionine | 4 | 2021 | 102 | 1.170 |
Why?
|
| Radiosurgery | 7 | 2022 | 106 | 1.170 |
Why?
|
| Estradiol | 2 | 2022 | 534 | 1.160 |
Why?
|
| Radiation Protection | 3 | 2016 | 54 | 1.150 |
Why?
|
| Middle Aged | 66 | 2024 | 25849 | 1.140 |
Why?
|
| Progesterone | 2 | 2022 | 624 | 1.140 |
Why?
|
| Menstrual Cycle | 2 | 2017 | 35 | 1.130 |
Why?
|
| Brain Neoplasms | 13 | 2014 | 1210 | 1.120 |
Why?
|
| Humans | 132 | 2024 | 122633 | 1.100 |
Why?
|
| Head and Neck Neoplasms | 5 | 2018 | 481 | 1.010 |
Why?
|
| Radiotherapy, Image-Guided | 6 | 2016 | 14 | 1.000 |
Why?
|
| Antineoplastic Agents | 11 | 2018 | 1675 | 0.980 |
Why?
|
| Radiation Oncology | 3 | 2022 | 23 | 0.960 |
Why?
|
| Prodrugs | 7 | 2004 | 59 | 0.960 |
Why?
|
| Neoplasm Staging | 18 | 2022 | 1215 | 0.940 |
Why?
|
| Prognosis | 20 | 2022 | 4488 | 0.930 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2018 | 143 | 0.890 |
Why?
|
| Treatment Failure | 8 | 2017 | 338 | 0.870 |
Why?
|
| Rectal Diseases | 3 | 2016 | 18 | 0.780 |
Why?
|
| Stomatitis | 3 | 2018 | 13 | 0.770 |
Why?
|
| Affect | 2 | 2022 | 154 | 0.740 |
Why?
|
| Follow-Up Studies | 18 | 2020 | 5019 | 0.720 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2018 | 59 | 0.710 |
Why?
|
| Haplotypes | 3 | 2016 | 515 | 0.700 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2018 | 354 | 0.690 |
Why?
|
| Survival Analysis | 10 | 2019 | 1466 | 0.680 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2024 | 140 | 0.670 |
Why?
|
| Disease-Free Survival | 10 | 2017 | 858 | 0.660 |
Why?
|
| Combined Modality Therapy | 12 | 2019 | 1240 | 0.640 |
Why?
|
| Kallikreins | 3 | 2015 | 26 | 0.640 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2015 | 25 | 0.630 |
Why?
|
| Analysis of Variance | 10 | 2017 | 1003 | 0.630 |
Why?
|
| Electrons | 1 | 2018 | 24 | 0.620 |
Why?
|
| Financial Support | 1 | 2018 | 8 | 0.600 |
Why?
|
| Photons | 1 | 2018 | 48 | 0.600 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2016 | 713 | 0.590 |
Why?
|
| Craniospinal Irradiation | 1 | 2018 | 58 | 0.590 |
Why?
|
| Age Factors | 7 | 2017 | 2788 | 0.580 |
Why?
|
| Spine | 1 | 2018 | 143 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 79 | 0.580 |
Why?
|
| Survival Rate | 11 | 2019 | 1992 | 0.580 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 85 | 0.580 |
Why?
|
| Conflict of Interest | 1 | 2018 | 67 | 0.570 |
Why?
|
| Attentional Blink | 1 | 2016 | 1 | 0.560 |
Why?
|
| Facial Recognition | 1 | 2016 | 7 | 0.550 |
Why?
|
| Follicular Phase | 1 | 2016 | 17 | 0.540 |
Why?
|
| Luteal Phase | 1 | 2016 | 10 | 0.540 |
Why?
|
| Treatment Outcome | 24 | 2022 | 12055 | 0.530 |
Why?
|
| Neoplasm Metastasis | 9 | 2019 | 648 | 0.520 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 52 | 0.520 |
Why?
|
| Retrospective Studies | 23 | 2020 | 15916 | 0.510 |
Why?
|
| Neoplasm Invasiveness | 6 | 2017 | 602 | 0.510 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 6341 | 0.510 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 542 | 0.500 |
Why?
|
| Sexual Behavior | 1 | 2017 | 234 | 0.500 |
Why?
|
| Cisplatin | 3 | 2021 | 242 | 0.500 |
Why?
|
| Cerebellar Neoplasms | 1 | 2018 | 282 | 0.490 |
Why?
|
| Hydrogels | 3 | 2020 | 77 | 0.490 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2014 | 20 | 0.480 |
Why?
|
| Flucytosine | 5 | 2006 | 17 | 0.480 |
Why?
|
| Medulloblastoma | 1 | 2018 | 338 | 0.480 |
Why?
|
| Decision Making | 4 | 2021 | 648 | 0.470 |
Why?
|
| Mathematics | 1 | 2014 | 98 | 0.470 |
Why?
|
| Cytosine Deaminase | 6 | 2006 | 20 | 0.460 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 1085 | 0.460 |
Why?
|
| Nomograms | 1 | 2014 | 36 | 0.450 |
Why?
|
| Mental Recall | 1 | 2014 | 138 | 0.450 |
Why?
|
| Time Factors | 15 | 2024 | 6188 | 0.430 |
Why?
|
| Urethra | 2 | 2016 | 82 | 0.430 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 1297 | 0.430 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2018 | 1003 | 0.430 |
Why?
|
| Biopsy | 4 | 2015 | 1238 | 0.420 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2011 | 3506 | 0.420 |
Why?
|
| Neoplasms | 5 | 2023 | 2746 | 0.410 |
Why?
|
| Carcinoma | 2 | 2012 | 277 | 0.410 |
Why?
|
| Prospective Studies | 15 | 2024 | 6012 | 0.410 |
Why?
|
| Genetic Therapy | 6 | 2006 | 661 | 0.400 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 519 | 0.390 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 1411 | 0.390 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 712 | 0.390 |
Why?
|
| Nucleoside Deaminases | 3 | 2000 | 26 | 0.380 |
Why?
|
| Adult | 21 | 2023 | 28881 | 0.380 |
Why?
|
| Penile Erection | 3 | 2018 | 67 | 0.380 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 439 | 0.370 |
Why?
|
| Cohort Studies | 10 | 2019 | 4686 | 0.370 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2018 | 651 | 0.370 |
Why?
|
| Protons | 3 | 2020 | 91 | 0.370 |
Why?
|
| Medical Oncology | 2 | 2014 | 213 | 0.360 |
Why?
|
| Neurofibromatosis 1 | 1 | 2011 | 59 | 0.350 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 1424 | 0.350 |
Why?
|
| Risk Assessment | 6 | 2017 | 3316 | 0.350 |
Why?
|
| Carboxypeptidases | 2 | 2000 | 16 | 0.340 |
Why?
|
| Carmustine | 3 | 2006 | 26 | 0.330 |
Why?
|
| Tumor Burden | 4 | 2013 | 230 | 0.310 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2006 | 99 | 0.310 |
Why?
|
| Risk | 3 | 2019 | 746 | 0.310 |
Why?
|
| Gastrointestinal Hemorrhage | 3 | 2016 | 223 | 0.300 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2008 | 52 | 0.300 |
Why?
|
| Risk Factors | 11 | 2019 | 9943 | 0.300 |
Why?
|
| Young Adult | 7 | 2023 | 8817 | 0.290 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2021 | 164 | 0.290 |
Why?
|
| Patient Outcome Assessment | 2 | 2021 | 94 | 0.290 |
Why?
|
| Protein Kinases | 1 | 2009 | 330 | 0.280 |
Why?
|
| Longitudinal Studies | 4 | 2024 | 1306 | 0.280 |
Why?
|
| Female | 21 | 2024 | 65117 | 0.280 |
Why?
|
| Biopsy, Needle | 6 | 2017 | 230 | 0.270 |
Why?
|
| Drug Delivery Systems | 1 | 2007 | 180 | 0.270 |
Why?
|
| Sarcoma | 1 | 2009 | 193 | 0.270 |
Why?
|
| Ependymoma | 1 | 2007 | 133 | 0.260 |
Why?
|
| Central Nervous System | 1 | 2007 | 253 | 0.260 |
Why?
|
| Cause of Death | 3 | 2013 | 455 | 0.260 |
Why?
|
| Fluorouracil | 4 | 2007 | 129 | 0.250 |
Why?
|
| Erectile Dysfunction | 4 | 2017 | 170 | 0.250 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2022 | 33 | 0.250 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2015 | 1229 | 0.240 |
Why?
|
| Pentosyltransferases | 1 | 2004 | 18 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 12 | 2007 | 1063 | 0.240 |
Why?
|
| Chemoradiotherapy | 2 | 2016 | 101 | 0.230 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2006 | 287 | 0.230 |
Why?
|
| Receptor, ErbB-2 | 1 | 2007 | 495 | 0.230 |
Why?
|
| Movement | 2 | 2018 | 165 | 0.230 |
Why?
|
| Oligospermia | 1 | 2023 | 57 | 0.220 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 321 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2016 | 178 | 0.220 |
Why?
|
| Health Status | 2 | 2016 | 373 | 0.220 |
Why?
|
| Lung Neoplasms | 4 | 2022 | 1577 | 0.200 |
Why?
|
| Subtilisins | 2 | 1999 | 10 | 0.200 |
Why?
|
| Animals | 23 | 2016 | 33618 | 0.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 333 | 0.190 |
Why?
|
| Testis | 1 | 2023 | 405 | 0.190 |
Why?
|
| Urology | 1 | 2022 | 74 | 0.190 |
Why?
|
| Adolescent | 8 | 2023 | 18987 | 0.190 |
Why?
|
| Models, Statistical | 3 | 2012 | 450 | 0.180 |
Why?
|
| Apoptosis | 7 | 2016 | 1782 | 0.180 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2024 | 234 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2011 | 757 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2023 | 187 | 0.180 |
Why?
|
| Infertility, Male | 1 | 2023 | 262 | 0.180 |
Why?
|
| United States | 6 | 2021 | 10559 | 0.180 |
Why?
|
| Dose-Response Relationship, Radiation | 4 | 2018 | 68 | 0.180 |
Why?
|
| Hearing Loss | 1 | 2021 | 131 | 0.180 |
Why?
|
| DNA Damage | 3 | 2016 | 506 | 0.170 |
Why?
|
| Cancer Care Facilities | 1 | 2020 | 30 | 0.170 |
Why?
|
| Patient Satisfaction | 2 | 2013 | 475 | 0.170 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 3283 | 0.170 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2010 | 25 | 0.170 |
Why?
|
| Phenylalanine | 1 | 2000 | 120 | 0.170 |
Why?
|
| Rhabdoid Tumor | 1 | 2019 | 49 | 0.160 |
Why?
|
| Seminal Vesicles | 3 | 2016 | 52 | 0.160 |
Why?
|
| Thiohydantoins | 1 | 2018 | 3 | 0.160 |
Why?
|
| Program Development | 1 | 2020 | 189 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 3341 | 0.160 |
Why?
|
| Teratoma | 1 | 2019 | 123 | 0.150 |
Why?
|
| Disease Progression | 5 | 2015 | 2024 | 0.150 |
Why?
|
| Self-Help Devices | 1 | 2018 | 11 | 0.150 |
Why?
|
| Neoplasms, Experimental | 1 | 1999 | 211 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 1 | 2020 | 208 | 0.150 |
Why?
|
| Rats | 8 | 2008 | 3620 | 0.150 |
Why?
|
| Electroencephalography | 1 | 2022 | 859 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2016 | 876 | 0.150 |
Why?
|
| Methotrexate | 1 | 2000 | 342 | 0.150 |
Why?
|
| Hospitals, Veterans | 1 | 2020 | 355 | 0.150 |
Why?
|
| Catheters | 1 | 2018 | 89 | 0.140 |
Why?
|
| Radiation, Ionizing | 2 | 2016 | 42 | 0.140 |
Why?
|
| Artifacts | 1 | 2018 | 103 | 0.140 |
Why?
|
| Orgasm | 1 | 2017 | 7 | 0.140 |
Why?
|
| Healthy Volunteers | 1 | 2017 | 131 | 0.140 |
Why?
|
| Child, Preschool | 6 | 2019 | 13794 | 0.140 |
Why?
|
| Area Under Curve | 2 | 2010 | 309 | 0.140 |
Why?
|
| Causality | 1 | 2016 | 78 | 0.140 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 676 | 0.140 |
Why?
|
| Quality Indicators, Health Care | 2 | 2020 | 213 | 0.140 |
Why?
|
| Radiometry | 2 | 2018 | 38 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 335 | 0.130 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 215 | 0.130 |
Why?
|
| Brain Stem Neoplasms | 1 | 2016 | 39 | 0.130 |
Why?
|
| Deoxycytidine | 1 | 2016 | 77 | 0.130 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2016 | 30 | 0.130 |
Why?
|
| Spiro Compounds | 1 | 2016 | 13 | 0.130 |
Why?
|
| Saliva | 1 | 2016 | 113 | 0.130 |
Why?
|
| Urologic Diseases | 1 | 2016 | 44 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 67 | 0.130 |
Why?
|
| Administration, Oral | 1 | 2018 | 670 | 0.130 |
Why?
|
| Child | 7 | 2023 | 24086 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2013 | 1683 | 0.130 |
Why?
|
| Consumer Health Information | 1 | 2015 | 25 | 0.130 |
Why?
|
| COS Cells | 6 | 2006 | 273 | 0.120 |
Why?
|
| Iodine Radioisotopes | 1 | 2015 | 75 | 0.120 |
Why?
|
| ROC Curve | 3 | 2013 | 554 | 0.120 |
Why?
|
| Urinary Incontinence | 3 | 2024 | 69 | 0.120 |
Why?
|
| Indoles | 1 | 2016 | 181 | 0.120 |
Why?
|
| Physicians | 1 | 2021 | 583 | 0.120 |
Why?
|
| Fludrocortisone | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hormone Antagonists | 1 | 2014 | 63 | 0.120 |
Why?
|
| Counseling | 2 | 2014 | 218 | 0.120 |
Why?
|
| Audiovisual Aids | 1 | 2014 | 25 | 0.120 |
Why?
|
| Postoperative Complications | 3 | 2015 | 2996 | 0.120 |
Why?
|
| Osteochondroma | 1 | 2014 | 5 | 0.120 |
Why?
|
| Aftercare | 1 | 2015 | 145 | 0.120 |
Why?
|
| Whole-Body Irradiation | 1 | 2014 | 65 | 0.110 |
Why?
|
| Mice, Nude | 4 | 2009 | 691 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2014 | 120 | 0.110 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1576 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 262 | 0.110 |
Why?
|
| Immunohistochemistry | 5 | 2017 | 1684 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2014 | 80 | 0.110 |
Why?
|
| Radio Waves | 1 | 2013 | 7 | 0.110 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2014 | 81 | 0.110 |
Why?
|
| Comparative Effectiveness Research | 1 | 2013 | 66 | 0.110 |
Why?
|
| Mice | 11 | 2009 | 17430 | 0.110 |
Why?
|
| Transduction, Genetic | 3 | 2006 | 277 | 0.110 |
Why?
|
| Fatigue | 2 | 2017 | 217 | 0.110 |
Why?
|
| Sexual Dysfunction, Physiological | 2 | 2015 | 71 | 0.110 |
Why?
|
| Fecal Incontinence | 1 | 2013 | 69 | 0.100 |
Why?
|
| Predictive Value of Tests | 6 | 2017 | 2100 | 0.100 |
Why?
|
| Confidence Intervals | 1 | 2013 | 277 | 0.100 |
Why?
|
| Electromagnetic Fields | 1 | 2012 | 26 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 279 | 0.100 |
Why?
|
| Linear Models | 1 | 2014 | 664 | 0.100 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 223 | 0.100 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2011 | 8 | 0.100 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 2837 | 0.100 |
Why?
|
| Neoplasm Transplantation | 3 | 2009 | 369 | 0.100 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2007 | 23 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 280 | 0.100 |
Why?
|
| Depression | 2 | 2017 | 1220 | 0.090 |
Why?
|
| Hypothalamic Neoplasms | 1 | 2011 | 3 | 0.090 |
Why?
|
| Lymphoma | 1 | 2014 | 321 | 0.090 |
Why?
|
| Aspirin | 1 | 2013 | 224 | 0.090 |
Why?
|
| Infant | 5 | 2019 | 12272 | 0.090 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2011 | 19 | 0.090 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 303 | 0.090 |
Why?
|
| Surveys and Questionnaires | 3 | 2017 | 3648 | 0.090 |
Why?
|
| Communication | 1 | 2014 | 510 | 0.090 |
Why?
|
| Registries | 1 | 2016 | 1379 | 0.090 |
Why?
|
| Mucositis | 1 | 2010 | 18 | 0.090 |
Why?
|
| Prevalence | 1 | 2016 | 2388 | 0.090 |
Why?
|
| Enzyme Activation | 3 | 2002 | 619 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 141 | 0.090 |
Why?
|
| Stereoisomerism | 1 | 2010 | 103 | 0.090 |
Why?
|
| Biological Availability | 1 | 2010 | 128 | 0.090 |
Why?
|
| Incidence | 2 | 2019 | 3040 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 2 | 2010 | 423 | 0.090 |
Why?
|
| Nausea | 1 | 2010 | 97 | 0.080 |
Why?
|
| Carboxypeptidases A | 2 | 2000 | 4 | 0.080 |
Why?
|
| Bone Neoplasms | 1 | 2014 | 426 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 4257 | 0.080 |
Why?
|
| Models, Theoretical | 1 | 2011 | 351 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 586 | 0.080 |
Why?
|
| Neurosurgery | 1 | 2010 | 76 | 0.080 |
Why?
|
| Vomiting | 1 | 2010 | 115 | 0.080 |
Why?
|
| Retroviridae | 2 | 1999 | 194 | 0.080 |
Why?
|
| Luminescent Measurements | 2 | 2006 | 57 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 1033 | 0.080 |
Why?
|
| Transcriptome | 1 | 2015 | 907 | 0.080 |
Why?
|
| Hemodynamics | 2 | 2010 | 848 | 0.080 |
Why?
|
| Endothelium | 1 | 2009 | 71 | 0.080 |
Why?
|
| Microcirculation | 1 | 2009 | 93 | 0.080 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 821 | 0.080 |
Why?
|
| Radiation-Protective Agents | 1 | 2008 | 17 | 0.080 |
Why?
|
| fas Receptor | 2 | 1998 | 41 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2006 | 240 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2012 | 585 | 0.070 |
Why?
|
| Comorbidity | 1 | 2012 | 1491 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 422 | 0.070 |
Why?
|
| Sirolimus | 1 | 2009 | 219 | 0.070 |
Why?
|
| Biomarkers | 2 | 2018 | 2935 | 0.070 |
Why?
|
| Radiography | 3 | 2015 | 815 | 0.070 |
Why?
|
| Gene Targeting | 1 | 2007 | 179 | 0.070 |
Why?
|
| Luciferases, Firefly | 1 | 2006 | 14 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2006 | 867 | 0.070 |
Why?
|
| Biological Clocks | 1 | 2006 | 28 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor D | 1 | 2006 | 6 | 0.070 |
Why?
|
| Capillary Permeability | 1 | 2006 | 78 | 0.070 |
Why?
|
| Gliosarcoma | 1 | 2006 | 9 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2009 | 428 | 0.070 |
Why?
|
| Bystander Effect | 1 | 2006 | 7 | 0.070 |
Why?
|
| Viral Structural Proteins | 1 | 2006 | 47 | 0.060 |
Why?
|
| Genes, p53 | 1 | 2006 | 212 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 1240 | 0.060 |
Why?
|
| Injections, Intraventricular | 1 | 2005 | 65 | 0.060 |
Why?
|
| Rotation | 2 | 2018 | 51 | 0.060 |
Why?
|
| Injections, Intralesional | 1 | 2005 | 48 | 0.060 |
Why?
|
| Feedback | 1 | 2006 | 160 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 1192 | 0.060 |
Why?
|
| Models, Biological | 2 | 2009 | 1434 | 0.060 |
Why?
|
| Half-Life | 1 | 2005 | 156 | 0.060 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 997 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2009 | 528 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2005 | 252 | 0.060 |
Why?
|
| Peptide Hydrolases | 1 | 2006 | 141 | 0.060 |
Why?
|
| Fluorodeoxyuridylate | 1 | 2004 | 2 | 0.060 |
Why?
|
| Artificial Gene Fusion | 1 | 2004 | 11 | 0.060 |
Why?
|
| Fluorine | 1 | 2004 | 15 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2005 | 374 | 0.060 |
Why?
|
| Optic Nerve Glioma | 1 | 2004 | 21 | 0.060 |
Why?
|
| Algorithms | 1 | 2011 | 1583 | 0.060 |
Why?
|
| Survivors | 3 | 2015 | 345 | 0.060 |
Why?
|
| Blood Volume | 3 | 2010 | 80 | 0.060 |
Why?
|
| Ethanol | 1 | 2005 | 162 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 1002 | 0.060 |
Why?
|
| Fiducial Markers | 2 | 2015 | 3 | 0.060 |
Why?
|
| Research Design | 1 | 2007 | 654 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 469 | 0.060 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2006 | 423 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2006 | 414 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2024 | 77 | 0.050 |
Why?
|
| Sperm Count | 1 | 2023 | 75 | 0.050 |
Why?
|
| Luteinizing Hormone | 1 | 2023 | 119 | 0.050 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2023 | 185 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2022 | 710 | 0.050 |
Why?
|
| Radiation Oncologists | 1 | 2022 | 3 | 0.050 |
Why?
|
| Genetic Vectors | 3 | 2006 | 924 | 0.050 |
Why?
|
| Urologists | 1 | 2022 | 10 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 1334 | 0.050 |
Why?
|
| Cognition | 1 | 2007 | 733 | 0.050 |
Why?
|
| Radiation Dosage | 2 | 2015 | 131 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 159 | 0.050 |
Why?
|
| Auditory Threshold | 1 | 2021 | 17 | 0.050 |
Why?
|
| Gene Expression | 2 | 2004 | 1568 | 0.050 |
Why?
|
| Quality Improvement | 2 | 2020 | 621 | 0.050 |
Why?
|
| Escherichia coli Proteins | 1 | 2004 | 303 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 1015 | 0.050 |
Why?
|
| Cell Division | 2 | 2000 | 778 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2002 | 414 | 0.050 |
Why?
|
| Recombinant Proteins | 3 | 2000 | 1390 | 0.050 |
Why?
|
| India | 1 | 2021 | 217 | 0.050 |
Why?
|
| DNA Primers | 2 | 1999 | 661 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 669 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2391 | 0.050 |
Why?
|
| Antifungal Agents | 2 | 2000 | 293 | 0.040 |
Why?
|
| Trypsin | 1 | 2000 | 95 | 0.040 |
Why?
|
| Peer Review | 1 | 2020 | 41 | 0.040 |
Why?
|
| Rats, Inbred F344 | 3 | 2006 | 101 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2020 | 234 | 0.040 |
Why?
|
| Heart Failure | 1 | 2012 | 2123 | 0.040 |
Why?
|
| Michigan | 1 | 2019 | 39 | 0.040 |
Why?
|
| Patient Participation | 1 | 2021 | 218 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 462 | 0.040 |
Why?
|
| Male Urogenital Diseases | 1 | 2018 | 12 | 0.040 |
Why?
|
| Protein Precursors | 1 | 1999 | 149 | 0.040 |
Why?
|
| Brain | 2 | 2013 | 2942 | 0.040 |
Why?
|
| Catalytic Domain | 1 | 1999 | 155 | 0.040 |
Why?
|
| Escherichia coli | 2 | 2004 | 980 | 0.040 |
Why?
|
| Sexuality | 1 | 2017 | 15 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 1999 | 231 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 447 | 0.040 |
Why?
|
| Mutagenesis | 1 | 1999 | 347 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 423 | 0.040 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 893 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2017 | 6 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2040 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 1999 | 277 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 729 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2019 | 383 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1999 | 354 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 57 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 71 | 0.030 |
Why?
|
| Sample Size | 1 | 2016 | 79 | 0.030 |
Why?
|
| Cystitis | 1 | 2016 | 50 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 611 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2016 | 245 | 0.030 |
Why?
|
| Cystectomy | 1 | 2016 | 152 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 676 | 0.030 |
Why?
|
| Estramustine | 1 | 2015 | 4 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 298 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 2821 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 15 | 0.030 |
Why?
|
| Breast | 1 | 2017 | 214 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2015 | 60 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 117 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2016 | 163 | 0.030 |
Why?
|
| Caspase 3 | 2 | 2007 | 131 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2015 | 88 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2015 | 122 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2016 | 242 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1468 | 0.030 |
Why?
|
| Urinary Tract | 1 | 2015 | 60 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 171 | 0.030 |
Why?
|
| Base Sequence | 1 | 1999 | 3093 | 0.030 |
Why?
|
| Propensity Score | 1 | 2015 | 203 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2013 | 35 | 0.030 |
Why?
|
| Mechanical Phenomena | 1 | 2013 | 15 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 48 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2013 | 55 | 0.030 |
Why?
|
| Calibration | 1 | 2013 | 89 | 0.030 |
Why?
|
| Bortezomib | 1 | 2013 | 73 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 157 | 0.030 |
Why?
|
| Esophageal Neoplasms | 1 | 1997 | 360 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2014 | 200 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 1089 | 0.030 |
Why?
|
| Pyrazines | 1 | 2013 | 73 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2013 | 69 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 959 | 0.030 |
Why?
|
| Uncertainty | 1 | 2013 | 99 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 352 | 0.030 |
Why?
|
| Self Report | 1 | 2015 | 506 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2014 | 252 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1162 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 374 | 0.020 |
Why?
|
| Consensus | 1 | 2014 | 606 | 0.020 |
Why?
|
| Androgens | 1 | 2013 | 256 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2002 | 151 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 48 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2010 | 107 | 0.020 |
Why?
|
| Forecasting | 1 | 2011 | 355 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2010 | 210 | 0.020 |
Why?
|
| Penis | 1 | 2009 | 97 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1670 | 0.020 |
Why?
|
| Veterans | 1 | 2020 | 1721 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2008 | 51 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2008 | 118 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 1998 | 213 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2306 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 498 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 2478 | 0.020 |
Why?
|
| Microscopy, Confocal | 2 | 1999 | 348 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2009 | 397 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2017 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2007 | 157 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2007 | 240 | 0.020 |
Why?
|
| Contrast Media | 1 | 2010 | 469 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8064 | 0.020 |
Why?
|
| RNA, Antisense | 1 | 2006 | 35 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 155 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2815 | 0.020 |
Why?
|
| Gene Fusion | 1 | 2006 | 55 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 462 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1787 | 0.020 |
Why?
|
| Perfusion | 1 | 2006 | 197 | 0.020 |
Why?
|
| Genetic Engineering | 1 | 2006 | 161 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 330 | 0.010 |
Why?
|
| Extracellular Fluid | 1 | 2004 | 12 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1864 | 0.010 |
Why?
|
| Thymidylate Synthase | 1 | 2004 | 21 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2006 | 447 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2006 | 351 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2008 | 876 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2004 | 234 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 1293 | 0.010 |
Why?
|
| Plasmids | 1 | 2004 | 511 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2006 | 604 | 0.010 |
Why?
|
| Luciferases | 1 | 2002 | 137 | 0.010 |
Why?
|
| DNA | 2 | 1998 | 1591 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 247 | 0.010 |
Why?
|
| Cell Line | 1 | 2006 | 2774 | 0.010 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2000 | 12 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 53 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2000 | 64 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 123 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 308 | 0.010 |
Why?
|
| Furin | 1 | 1999 | 7 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 1999 | 25 | 0.010 |
Why?
|
| Fibrillins | 1 | 1999 | 31 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 789 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 317 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 258 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1998 | 122 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1998 | 118 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1998 | 462 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1998 | 288 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 300 | 0.010 |
Why?
|
| Epithelium | 1 | 1997 | 366 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 456 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 4200 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 1068 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1997 | 459 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1998 | 1102 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1998 | 804 | 0.010 |
Why?
|
| Peptides | 1 | 1998 | 798 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 1584 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 1997 | 341 | 0.010 |
Why?
|